Navigation Links
Isis Pharmaceuticals to Present at the 2012 Citi Global Health Care Conference
Date:2/21/2012

CARLSBAD, Calif., Feb. 21, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi's 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 2:00 p.m. ET at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Royal Philips (NYSE: ... availability of its portfolio of diagnostic X-ray ... Opta[i] , ProGrade and PrimaryDiagnost[ii]. With new releases ... the U.S., and availability of all these solutions ... customers innovative solutions designed to meet the needs ...
(Date:11/26/2014)... 2014 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... previously announced concurrent financing transactions resulting in gross ... offering expenses, Lexicon anticipates net proceeds of approximately ... of: , a public offering of ... registration statement that has been declared effective by ...
(Date:11/26/2014)... Scott Steiger lives in St. Louis ... the past 20 years, he,s traveled extensively and prior to that, ... six of the seven continents. Travel is a big part of ... - http://photos.prnewswire.com/prnh/20141126/161077 So when he designs ... of what,s required. His latest creation is the Road ...
Breaking Medicine Technology:Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2
... 2007/PRNewswire-FirstCall/ -- Bristol-Myers,Squibb Company (NYSE: BMY) today ... that treatment with Baraclude (entecavir),demonstrated greater viral ... a result that was also seen at ... from an open-label, randomized viral kinetics study,of ...
... shows ability to limit inflammation in models ... presented at,Digestive Disease Week -, WASHINGTON, May ... Health today announced results from two studies,that ... bacterial strain of human origin, Bifantis(R),(Bifidobacterium infantis ...
Cached Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 2New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 3
(Date:11/26/2014)... November 27, 2014 iFitDress.com, a well-known ... collection of sweet 16 cocktail dresses . Included ... 16 cocktail gowns. Furthermore, all of these charming outfits ... off. , The company has promised that all of ... finest materials. It is worth mentioning that all of ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Deaf teens have stronger language and ... early age, a new study suggests. Researchers looked at ... with permanent hearing loss through an infant screening program conducted ... age 8 found that those who were screened by the ... reading skills than deaf children who weren,t screened as infants. ...
(Date:11/26/2014)... -- New regulations to reduce emissions of the smog-causing ... Wednesday by the U.S. Environmental Protection Agency. Ozone ... death. The new rules would lower the current ... to between 65 to 70 parts per billion, the ... with the latest science will clean up our air, ...
(Date:11/26/2014)... The report “Laboratory Information System/LIS Market by Type ... User Labs (Clinical, Molecular Diagnostic, Blood Bank, Anatomic ... Forecast to 2019” provides a detailed overview of ... trends, and strategies impacting the LIS market along ... and market growth. , Browse 85 market data ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Increasing ... which include image guided surgeries has paved way ... injectors. Rising incidence of various types of cancers ... proportionate increase in demand for these owing to ... of contrast media injectors market can also be ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Trendy Sweet 16 Cocktail Dresses Unveiled 2Health News:Spotting Hearing Problems in Infancy May Boost Reading Skills in Deaf Teens 2Health News:EPA Issues Tougher Rules on Ozone Emissions 2Health News:EPA Issues Tougher Rules on Ozone Emissions 3Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3
... suggests brains of heavy individuals may be wired ... brain circuitry that controls appetite might be wired differently ... obesity, California researchers suggest. , The study was conducted ... lead to novel obesity treatments, said Philip Smith, director ...
... Leading medical-device manufacturer replaces spreadsheet-based process with ... Xactly ... Xactly Corporation, the leader,in on-demand sales performance management, ... leading provider of products designed to,enhance the diagnosis and ...
... is a,statement by James P. Firman, chair of the ... budget proposal :, Senior organizations are deeply disappointed ... The budget proposes draconian cuts of almost,$200 billion to ... threatening harm to millions of older Americans., It ...
... a statement,by Daniel W. Jones, M.D., American Heart Association ... an opportunity to leave his,mark in the fight against ... Instead, his proposal will cut resources that would,bring us ... combating heart,disease and stroke, but that momentum will be ...
... LIONVILLE, Pa., Feb. 5 West Pharmaceutical,Services, Inc. (NYSE: ... Jr.,Ph.D., Chairman and Chief Executive Officer, and William Federici, ... Global Healthcare,Services Conference at 3:00 p.m. on February 11, ... the corporate presentation document will be posted on the,investor ...
... Feb. 5 BIOSAFE Laboratories, Inc.,the developer of ... States distributor, have announced the availability of a ... to help identify diabetic and,pre-diabetic children and adolescents. ... comprised of an immediate fasting glucose reading and,a ...
Cached Medicine News:Health News:Born to Be Obese? 2Health News:Born to Be Obese? 3Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 2Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 3Health News:Statement by James P. Firman, Chair Leadership Council of Aging Organizations (LCAO) on the President's FY2009 Budget Proposal 2Health News:Statement by Daniel W. Jones, M.D., American Heart Association President on President Bush's FY 2009 Budget Proposal 2Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessment Kits to U.S. School Children 2
... 1 (IGF-1) is a polypeptide of 70 amino ... number of related insulin-like growth factors present in ... homology with proinsulin and has a number of ... growth hormone (GH) dependent to a high degree, ...
...
...
...
Medicine Products: